Table 1 Comparison of clinicopathological characteristics and treatments between eligible and ineligible patients
Characteristics | Overall (N = 205) | OlympiA eligible (N = 60) | OlympiA ineligible (N = 145) | P value |
|---|---|---|---|---|
Age at diagnosis | ||||
Mean (SD) | 45.9 (13.6) | 43.5 (12.8) | 46.9 (13.8) | 0.094 |
Median [Min, Max] | 43.0 [25.0, 80.0] | 39.0 [25.0, 73.0] | 44.0 [25.0, 80.0] | |
Sex | ||||
Female | 198 (96.6%) | 58 (96.7%) | 140 (96.6%) | 1 |
Male | 7 (3.4%) | 2 (3.3%) | 5 (3.4%) | |
Race | ||||
White | 176 (85.9%) | 51 (85.0%) | 125 (86.2%) | 0.600 |
Asian or Pacific Islander | 9 (4.4%) | 2 (3.3%) | 7 (4.8%) | |
African American | 10 (4.9%) | 2 (3.3%) | 8 (5.5%) | |
Native American, Alaska Natives | 1 (0.5%) | 0 (0%) | 1 (0.7%) | |
Unknown | 9 (4.4%) | 5 (8.3%) | 4 (2.8%) | |
Menopausal status | ||||
Postmenopausal | 67 (32.7%) | 17 (28.3%) | 50 (34.5%) | 0.443 |
Premenopausal | 129 (62.9%) | 41 (68.3%) | 88 (60.7%) | |
Unknown | 9 (4.4%) | 2 (3.3%) | 7 (4.8%) | |
Gene | ||||
BRCA1 | 115 (56.1%) | 39 (65.0%) | 76 (52.4%) | 0.134 |
BRCA2 | 90 (43.9%) | 21 (35.0%) | 69 (47.6%) | |
Clinical presentation | ||||
Screen-detected | 76 (37.1%) | 14 (23.3%) | 62 (42.8%) | 0.026 |
Breast lump | 116 (56.5%) | 41 (68.4%) | 75 (51.8%) | |
Other breast/axillary symptoms | 13 (6.3%) | 5 (8.3%) | 8 (5.5%) | |
Tumor histology | ||||
Invasive ductal | 165 (80.5%) | 48 (80.0%) | 117 (80.7%) | 1 |
Invasive lobular | 16 (7.8%) | 5 (8.3%) | 11 (7.6%) | |
Mixed (IDC & ILC) | 20 (9.8%) | 6 (10.0%) | 14 (9.7%) | |
Other | 4 (1.9%) | 1 (1.7%) | 3 (2.1%) | |
Synchronous breast cancer | ||||
Yes | 15 (7.3%) | 4 (6.7%) | 11 (7.6%) | 1 |
No | 190 (92.7%) | 56 (93.3%) | 134 (92.4%) | |
Tumor Grade | ||||
I Low Grade | 7 (3.4%) | 0 (0%) | 7 (4.8%) | 0.046 |
II Intermediate Grade | 48 (23.4%) | 10 (16.7%) | 38 (26.2%) | |
III High Grade | 148 (72.2%) | 50 (83.3%) | 98 (67.6%) | |
Unknown | 2 (1.0%) | 0 (0%) | 2 (1.4%) | |
Subtype | ||||
HR+ | 113 (55.1%) | 20 (33.3%) | 93 (64.1%) | <0.001 |
HR-low (ER < 10% and/or PR < 10%) | 15 (13.3%) | 6 (30.0%) | 9 (9.7%) | |
TN | 92 (44.9%) | 40 (66.7%) | 52 (35.9%) | |
HER2 IHC score | ||||
0 | 94 (45.9%) | 31 (51.7%) | 63 (43.4%) | 0.188 |
1+ | 66 (32.2%) | 20 (33.3%) | 46 (31.7%) | |
2+ (with negative FISH) | 40 (19.5%) | 7 (11.7%) | 33 (22.8%) | |
Not done/Unknown | 5 (2.4%) | 2 (3.3%) | 3 (2.1%) | |
Stage | ||||
I | 83 (40.5%) | 5 (8.3%) | 78 (53.8%) | <0.001 |
II | 93 (45.4%) | 38 (63.3%) | 55 (37.9%) | |
III | 29 (14.1%) | 17 (28.3%) | 12 (8.3%) | |
Chemotherapy | ||||
Yes | 166 (81.0%) | 60 (100%) | 106 (73.1%) | <0.001 |
Adjuvant only | 59 (28.8%) | 10 (16.7%) | 49 (33.8%) | |
Neoadjuvant only | 56 (27.3%) | 12 (20.0%) | 44 (30.3%) | |
Both neoadjuvant and adjuvant | 51 (24.9%) | 38 (63.3%) | 13 (9.0%) | |
No | 39 (19.0%) | 0 (0%) | 39 (26.9%) | |
Received anthracyclines | ||||
Yes | 130 (78.3%) | 55 (91.7%) | 75 (70.8%) | 0.002 |
No | 36 (21.7%) | 5 (8.3%) | 31 (29.2%) | |
Received platinum | ||||
Yes | 32 (19.3%) | 19 (31.7%) | 13 (12.3%) | 0.005 |
No | 134 (80.7%) | 41 (68.3%) | 93 (87.7%) | |
Endocrine therapy (Among HR+ Patients) | ||||
Yes | 91 (80.5%) | 12 (60%) | 79 (84.9%) | 0.025 |
No | 22 (19.5%) | 8 (40%) | 14 (15.1%) | |
ODX performed? (Among HR+ Patients) | ||||
Performed | 50 (44.2%) | 2 (10%) | 48 (51.6%) | 0.001 |
Not performed | 63 (55.8%) | 18 (90%) | 45 (48.4%) | |
ODX Recurrence Score | ||||
Median [Min, Max] | 25.0 [10.0, 71.0] | 32.5 [30.0, 35.0] | 25.0 [10.0, 71.0] | – |
Genetic testing before diagnosis | ||||
Yes | 73 (35.6%) | 12 (20.0%) | 61 (42.1%) | 0.004 |
No | 132 (64.4%) | 48 (80.0%) | 84 (57.9%) | |
